WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway. [electronic resource]
Producer: 20180222Description: 79544-79556 p. digitalISSN:- 1949-2553
- Alkaloids -- pharmacology
- Animals
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Carcinoma, Hepatocellular -- drug therapy
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Self Renewal -- drug effects
- Dose-Response Relationship, Drug
- Doxorubicin -- pharmacology
- Drug Resistance, Neoplasm -- drug effects
- Epithelial Cell Adhesion Molecule -- genetics
- Gene Expression Regulation, Neoplastic
- Glycogen Synthase Kinase 3 beta -- metabolism
- Humans
- Inhibitory Concentration 50
- Liver Neoplasms -- drug therapy
- Male
- Mice, Inbred BALB C
- Mice, Nude
- Neoplastic Stem Cells -- drug effects
- Phenotype
- Proto-Oncogene Proteins c-akt -- metabolism
- Quinolizines -- pharmacology
- Time Factors
- Tumor Burden -- drug effects
- Wnt Signaling Pathway -- drug effects
- Xenograft Model Antitumor Assays
- beta Catenin -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.